Reuters: Novo Nordisk CagriSema trial result sets back obesity race
The combination of semaglutide and amylin analog cagrilintide is Novo's main answer to Eli Lilly's tirzepatide franchise.
MH
By Maren Holt · Senior Reporter, GLP-1
Feb 23 03:00 ETSource: Reuters
The wire
- 01Reuters reports a CagriSema trial outcome that Novo Nordisk investors read as a setback in its obesity competition with Eli Lilly.
- 02CagriSema is the lead amylin-plus-GLP-1 combination, so its data shape what prescribers and compounders can expect next in incretin therapy.
- 03Full trial details, endpoints and Novo's regulatory plans matter more than the initial market reaction; watch the company's own disclosure.
From the source
Read at reuters.comNovo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly